135 related articles for article (PubMed ID: 11677931)
1. Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.
Lu J; Gries JM; Verotta D; Sheiner LB
J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):343-62. PubMed ID: 11677931
[TBL] [Abstract][Full Text] [Related]
2. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
Mu S; Ludden TM
J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
[TBL] [Abstract][Full Text] [Related]
3. Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria.
Kshirsagar SA; Blaschke TF; Sheiner LB; Krygowski M; Acosta EP; Verotta D
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):35-55. PubMed ID: 17004125
[TBL] [Abstract][Full Text] [Related]
4. Population one-compartment pharmacokinetic analysis with missing dosage data.
Soy D; Beal SL; Sheiner LB
Clin Pharmacol Ther; 2004 Nov; 76(5):441-51. PubMed ID: 15536459
[TBL] [Abstract][Full Text] [Related]
5. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
6. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
7. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
Hashimoto Y; Sheiner LB
J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
[TBL] [Abstract][Full Text] [Related]
8. An alternative method for population pharmacokinetic data analysis under noncompliance.
Gupta P; Hutmacher MM; Frame B; Miller R
J Pharmacokinet Pharmacodyn; 2008 Apr; 35(2):219-33. PubMed ID: 18299967
[TBL] [Abstract][Full Text] [Related]
9. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
[TBL] [Abstract][Full Text] [Related]
10. The impact of compliance in pharmacokinetic studies.
Vrijens B; Goetghebeur E
Stat Methods Med Res; 1999 Sep; 8(3):247-62. PubMed ID: 10636337
[TBL] [Abstract][Full Text] [Related]
11. Quantifying the Effectiveness of Dose Individualization by Simulation for a Drug With Moderate Pharmacokinetic Variability.
Liefaard L; Chen C
Ther Drug Monit; 2015 Oct; 37(5):641-8. PubMed ID: 26378372
[TBL] [Abstract][Full Text] [Related]
12. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
13. Comparison of some control strategies for three-compartment PK/PD models.
Hu C; Lovejoy WS; Shafer SL
J Pharmacokinet Biopharm; 1994 Dec; 22(6):525-50. PubMed ID: 7473080
[TBL] [Abstract][Full Text] [Related]
14. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.
Vrijens B; Goetghebeur E
Stat Med; 2004 Feb; 23(4):531-44. PubMed ID: 14755387
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of population D-optimal designs via pharmacokinetic simulations.
Hooker AC; Foracchia M; Dodds MG; Vicini P
Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
[TBL] [Abstract][Full Text] [Related]
16. PK-DB: pharmacokinetics database for individualized and stratified computational modeling.
Grzegorzewski J; Brandhorst J; Green K; Eleftheriadou D; Duport Y; Barthorscht F; Köller A; Ke DYJ; De Angelis S; König M
Nucleic Acids Res; 2021 Jan; 49(D1):D1358-D1364. PubMed ID: 33151297
[TBL] [Abstract][Full Text] [Related]
17. Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.
Slavik RS; Jewesson PJ
Clin Pharmacokinet; 2003; 42(9):793-817. PubMed ID: 12882587
[TBL] [Abstract][Full Text] [Related]
18. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds.
Pelekis M; Gephart LA; Lerman SE
Regul Toxicol Pharmacol; 2001 Feb; 33(1):12-20. PubMed ID: 11259175
[TBL] [Abstract][Full Text] [Related]
19. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
20. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
